Please assess the completion status of the following clinical trial:

Trial Title: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients chronically infected with hepatitis C virus (HCV) genotype 1 or 4~* HCV RNA viral load of ≥100,000 IU/mL~* No previous exposure to interferon, pegIFNα, or RBV~* Results of a liver biopsy demonstrating absence of cirrhosis obtained ≤24 months prior to randomization. Compensated cirrhotics with Hepatitis C virus genotype 1 infection are eligible, but will be capped at 10% of the randomized study population (biopsy can be from any time period prior to randomization)~* Findings on ultrasound, computed tomography scan, or magnetic resonance imaging 12 months prior to randomization that do not demonstrate evidence of hepatocellular carcinoma~* Body mass index of 18 to 35 kg/m\^2~Exclusion Criteria:~* Positive for hepatitis B or HIV-1/HIV-2 antibody at screening~* Evidence of a medical condition associated with chronic liver disease other than HCV~* Evidence of decompensated cirrhosis based on radiologic criteria or biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg) (Type: EXPERIMENTAL): None
- Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg) (Type: EXPERIMENTAL): None
- Placebo plus peg-interferon alfa-2a and ribavirin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).